Prevalence and Pathogenicity of Omicron Varian



Abstract Views
532

Downloads
361

Citations

Share

##plugins.themes.bootstrap3.article.sidebar##

Submitted Sep 9, 2022
Published Oct 29, 2022
10.24018/ejmed.2022.4.5.1511

Abstract viewed = 532 times

Table of Contents

##plugins.themes.bootstrap3.article.main##

The surge of the Omicron variant has been studied in overall India, Delhi and Mumbai. The increase in the percentage share of the Omicron strain in total registered cases resulted in a surge of daily new infections. The pathogenicity of Original, Delta, and Omicron variants has been compared using the data collected at the Max Healthcare network in India. The Omicron wave was the least severe of all three waves. The third Omicron wave did not cause much damage due to hybrid immunity generated in the population as a result of vaccination and previous SARS-CoV-2 infection. The low pathogenic nature of the Omicron virus is also the reason for the less severe illnesses the variant caused. Hospitalization during the Omicron wave was just 10% of the Delta wave. The percentage of patients who needed oxygen support was the least during the Omicron wave (23.4%) followed by the Original (63%) and the Delta variant (74%). The less severe nature of the Omicron wave gave the hope of recovering from the deadly devastating COVID-19 pandemic. The symptoms of “long COVID” patients have been compared during all three waves. Nearly the same number of the patients at 5.3% and 5.16% had health issues during Original and Omicron waves, respectively whereas during the Delta surge 5.9% of patients with “long COVID” had symptoms.

Keywords: Delta variant, Omicron variant, Omicron pathogenicity, Omicron prevalence and transmissibility, SARS-CoV-2 mutation

Downloads

Download data is not yet available.

References

  1. Omicron subvariants BA.4, BA.5 confirmed for 1st time in Japan at airport quarantine. The Mainichi. [Internet] 2022 [cited 2022 May 13] Available from: https://mainichi.jp/english/articles/20220513/p2a/00m/0na/010000c
     Google Scholar
  2. COVID-19 Google news. [Internet] 2022 Available from: https://news.google.com/covid19/map?hl=en-US&gl=US&ceid=US%3Aen&mid=%2Fm%2F03_3d
     Google Scholar
  3. Everything you need to know about BA.5, the dominant strain spreading across Japan. The Japan Times. [Internet] 2022 [cited 2022 July 28] Available from: https://www.japantimes.co.jp/news/2022/07/28/national/science-health/COVID-surge-ba-5-explainer/
     Google Scholar
  4. Omicron variant less severe than Delta for children younger than 5 years: Study. The Indian Express. [Internet] 2022 [cited 2022 April 5] Available from: https://indianexpress.com/article/parenting/health-fitness/omicron-variant-less-severe-than-delta-for-children-younger-than-5-years-study-7852044/
     Google Scholar
  5. Wang L, Berger NA, Kaelber DC, Davis PB, Volkow ND, Xu R. Incidence rates and clinical outcomes of SARS-CoV-2 infection with the Omicron and Delta variants in children younger than 5 years in the US. JAMA Pediatrics. 2022.
    DOI  |   Google Scholar
  6. Some 10% suffer COVID-19 aftereffects one year after discharge: survey. The Japan Times. [Internet] 2022 [cited 2022 May 8] Available from: https://www.japantimes.co.jp/news/2022/05/08/national/science-health/COVID-19-aftereffects/
     Google Scholar
  7. Omicron is turning out to be a weak vaccine. The Japan Times. [Internet] 2022 [cited 2022 June 5] Available from: https://www.japantimes.co.jp/opinion/2022/06/05/commentary/world-commentary/COVID-19-omicron/
     Google Scholar
  8. COVID booster effective in preventing infection for 70% of population, Japan study says. The Japan Times. [Internet] 2022 [cited 2022 June 9] Available from: https://www.japantimes.co.jp/news/2022/06/09/national/science-health/third-COVID-shot-study/
     Google Scholar
  9. Japan looks to accelerate vaccine research and development with new government body. The Japan Times. [Internet] 2022 [cited 2022 April 3]. Available from: https://www.japantimes.co.jp/news/2022/04/03/national/science-health/japan-vaccine-development-agency/
     Google Scholar
  10. Shervani Z, Bhardwaj D, Sherwani A, Khan I, Qazi UY. COVID-19 infection in 8 big cities of India: The Dynamics of the Spread and Seropositivity. European Journal of Medical and Health Sciences. 2021; 3(6): 1-5.
    DOI  |   Google Scholar
  11. Shervani Z, Bhardwaj D, Nikhat R. COVID-19 infection in India: Seropositivity versus the Dynamics of the Spread. European Journal of Medical and Health Sciences. 2021; 3(4): 95-99.
    DOI  |   Google Scholar
  12. Shervani Z, Bhardwaj D, Nikhat R, Ibbrahim A, Hasan S, Khan I, et al. Serosurvey of Haryana and Odisha: COVID-19 Hybrid Immunity. European Journal of Medical and Health Sciences. 2022; 4(2): 27-32.
    DOI  |   Google Scholar
  13. Shervani Z, Bhardwaj D, Nikhat R, Ibbrahim A, Khan I, Qazi UY, et al. 4th National Sero Survey of India: Vaccine Generated Antibodies Enhancement. European Journal of Medical and Health Sciences. 2022; 4(1): 27-32.
    DOI  |   Google Scholar
  14. Shervani Z, Bhardwaj D, Nikhat R Ibbrahim A, Khan I, Hasan S, et al. 5th and 6th Sero Survey of Delhi: Vaccine Activated Antibodies Enhancement. European Journal of Medical and Health Sciences. 2022; 4(1): 61-66.
    DOI  |   Google Scholar
  15. Shervani Z. COVID-19 in Kerala: Health Index Theory. European Journal of Medical and Health Sciences. 2021; 3(2): 21-24.
    DOI  |   Google Scholar
  16. Shervani Z. COVID-19 in Kerala: The Dynamics of Spread and Health Index Theory. RAS Medical Science. 2021; 1(2): 1-3.
    DOI  |   Google Scholar
  17. Shervani Z, Bhardwaj D, Nikhat R. Dharavi Slums (Mumbai, India): The Petri Dish of COVID-19 Herd Immunity. European Journal of Medical and Health Sciences. 2021; 3(3): 38-41.
    DOI  |   Google Scholar
  18. Shervani Z, Khan I, Siddiqui NY, Khan T, Qazi UY. Viability of SARS-CoV-2 and Sanitization Methods. European Journal of Medical and Health Sciences. 2021; 3(1): 22-27.
    DOI  |   Google Scholar
  19. Shervani Z, Khan I, Qazi UY. COVID-19 vaccine. Advances in Infectious Diseases. 2020; 10(3): 195-210.
    DOI  |   Google Scholar
  20. Shervani Z, Khan I, Khan T, Qazi UY. World’s fastest supercomputer picks COVID-19 drug. Advances in Infectious Diseases. 2020; 10(3): 211-225.
    DOI  |   Google Scholar
  21. Shervani Z, Fatma K, Hasan S, Siddiquie A, Vuyyuru VPSR, Jamal N, et al. Mild Nature of SARS-CoV-2 Breakthrough Infections in Healthcare Workers in India, European Journal of Medical and Health Sciences. 2022; 4(4): 26-33.
    DOI  |   Google Scholar
  22. Shervani Z, Nikhat R, Hasan S, Qazi UY, Fatma K, Siddiquie A, et al. COVID-19 in India: Breakthrough Infections in Delta Wave. European Journal of Medical and Health Sciences. 2022; 4(4): 12-16.
    DOI  |   Google Scholar
  23. Shervani Z, Bhardwaj D, Purang M, Ibbrahim A, Vuyyuru VPSR, et al. The Omicron Variant: Prevalence, Transmissibility, and Pathogenicity. European Journal of Medical and Health Sciences. 2022; 4(3): 84-91.
    DOI  |   Google Scholar
  24. Shervani Z, Bhardwaj D, Hasan S, Qazi UY, Purang M, Ibbrahim A, et al. The Omicron Wave in India, Mumbai, and Delhi: Prevalence and Pathogenicity. European Journal of Medical and Health Sciences. 2022; 4(3): 123-30.
    DOI  |   Google Scholar
  25. New COVID-19 subvariant found in Japan patient. The Japan Times. [Internet] 2022 [cited 2022 April 28] Available from: https://www.japantimes.co.jp/news/2022/04/28/national/science-health/new-COVID19-subvariant-sendai/
     Google Scholar
  26. India: Coronavirus Pandemic Country Profile. [Internet] Available from: https://ourworldindata.org/coronavirus/country/india
     Google Scholar
  27. Genome sequencing shows 4 out of 5 cases reported in Jan caused by Omicron variant. The Times of India. [Internet] 2022 [cited 2022 January 28]. Available from: https://timesofindia.indiatimes.com/city/delhi/genome-sequencing-shows-4-out-of-5-cases-reported-in-jan-caused-by-omicron-variant/articleshow/89166954.cms
     Google Scholar
  28. Delhi: Genome sequencing reveals Omicron variant in 38% samples from city. India Today. [Internet] 2022 [cited 2021 December 30] Available from: https://www.indiatoday.in/coronavirus-outbreak/story/delhi-genome-sequencing-omicron-variant-in-samples-1893918-2021-12-29
     Google Scholar
  29. Omicron Found in 65% Delhi Samples Whose Report Came Between January 1-3. [Internet] [cited 2022 January 5] Available from: https://www.ndtv.com
     Google Scholar
  30. Delhi: Omicron Found In 80 Pc of Samples Taken From Deceased Patients Till Feb 22. Outlook. [Internet] [2022 February 25] Available from: https://www.outlookindia.com/national/delhi-omicron-found-in-80-pc-of-samples-taken-from-deceased-patients-till-feb-22-news-184101
     Google Scholar
  31. Delhi: Omicron variant found in 92% samples of deceased patients tested in Jan. Mint. [Internet] 2022 [2022 February 4] Available from: https://www.livemint.com/news/india/delhi-omicron-variant-found-in-92-samples-of-deceased-patients-tested-in-jan-11643989391173.html
     Google Scholar
  32. Delhi: Omicron found in 97 pc samples taken from deceased patients from Jan to March. The Print. [Internet] [2022 April 20] Available from: https://economictimes.indiatimes.com/news/india/delhi-omicron-found-in-97-pc-samples-taken-from-deceased-patients-from-jan-to-march/articleshow/90958606.cms?from=mdr
     Google Scholar
  33. Mumbai’s sixth genome sequencing: Omicron found in 2 per cent samples. [Internet] [cited 2021 December 16]. Available from: https://www.mid-day.com
     Google Scholar
  34. India’s delta and omicron hospitalisations show the power of vaccination. Quartz India [Internet] 2022 [cited 2022 January 25] Available from: https://qz.com/india/2116283/indias-COVID-hospitalisations-decline-from-delta-to-omicron/
     Google Scholar
  35. Long COVID takes toll as Japan patients seek answers. The Japan Times. [Internet] 2022 [cited 2022 June 3]. Available from: https://www.japantimes.co.jp/news/2022/06/03/national/science-health/japan-patients-long-COVID/
     Google Scholar


Most read articles by the same author(s)

1 2 > >>